STOCK TITAN

NervGen Pharma names Dr. Sam Jackson chief medical officer

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

NERVGEN PHARMA CORP. appointed Dr. Sam Jackson chief medical officer, effective December 7, 2026. His annualized salary under an agreement with wholly owned subsidiary NervGen US Inc. is $525,000; beginning in fiscal 2027, he is eligible for an annual bonus targeted at 40% of salary based on company and individual objectives. A separate agreement provides a $208,000 sign-on bonus in two installments: $100,000 following the effective date and $108,000 on or after March 31, 2027, subject to continued employment and specified adjustments. The company will grant options to purchase up to 1,156,135 common shares, at the common shares’ closing price on the effective date, exercisable for ten years and scheduled to vest over four years subject to continued service. It will also grant 50,000 restricted share units, which vest only if at least 150 RESTORE participants are randomized and enrolled by August 1, 2027, and Jackson remains in service through that milestone.

Filing Explained

For qualifying termination outside a change-in-control window, the agreement provides nine months of salary and health premiums for up to nine months. Within three months before or 12 months after a change in control, it provides 12 months of salary plus 100% of target bonus and premiums for up to 12 months. That change-in-control severance accelerates unvested time-based awards; all severance requires a general release.

Annualized base salary $525,000 Under the employment offer letter
Annual bonus target 40% of base salary Eligible beginning with fiscal year 2027; based on company and individual performance objectives
Sign-on bonus $208,000 One-time bonus payable in two installments, subject to stated conditions
Stock options Up to 1,156,135 common shares Grant effective December 7, 2026; subject to continued service for vesting
Option exercise period 10 years Options granted to Dr. Jackson
Restricted share units 50,000 units Vesting depends on the RESTORE enrollment milestone and continued service
RESTORE enrollment threshold At least 150 participants Must be randomized and enrolled on or before August 1, 2027 for the restricted share units to vest in full
Option vesting period 4 years 25.0% on the first anniversary, with the remaining 75.0% in 36 substantially equal monthly installments thereafter
restricted share units financial
"50,000 restricted share units"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
Compensation Recovery Policy financial
"All incentive-based compensation is subject to the Company's Compensation Recovery Policy"
COBRA regulatory
"employer portion of his health coverage premiums under COBRA"
COBRA is a U.S. federal law that lets employees and their dependents temporarily keep employer-sponsored health insurance after job loss, reduction in hours, or other qualifying events by paying the premiums themselves. Investors should care because offering COBRA can affect a company’s cash flow, administrative costs and legal disclosures when workforce changes occur—similar to a former club member paying to keep their membership active after leaving the club.
GRASSP Quantitative Prehension medical
"measured by GRASSP Quantitative Prehension"
motor-incomplete SCI medical
"chronic traumatic cervical motor-incomplete SCI"
open-label extension medical
"An optional 12-week open-label extension is planned"
An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Sam Jackson's compensation at NGEN?

His annualized base salary is $525,000, and beginning in fiscal 2027 he is eligible for an annual bonus targeted at 40% of salary. He will also receive a $208,000 sign-on bonus in two installments: $100,000 following the effective date and $108,000 on or after March 31, 2027, subject to continued employment and specified adjustments.

How do Sam Jackson's NGEN stock options vest?

Twenty-five percent is scheduled to vest on the first anniversary of the effective date, with the remaining 75.0% scheduled to vest in 36 substantially equal monthly installments thereafter, subject to continued service through each vesting date. The options are exercisable for ten years.

What must happen for Sam Jackson's NGEN restricted share units to vest?

At least 150 participants must be randomized and enrolled in RESTORE on or before August 1, 2027, and Jackson must remain in service through that milestone for the units to vest in full.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-43048

 

NERVGEN PHARMA CORP.

(Exact name of Registrant as specified in its charter)

 

N/A
(Translation of Registrant’s name)

 

1200 Brickell Avenue, Suite 1950 #IP
Miami, Florida 33131
Telephone: (778) 731-1711

(Address and telephone number of registrant’s principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F¨                Form 40-F x

 

 

 

 

 

 

EXPLANATORY NOTE

 

Chief Medical Officer Appointment

 

On November 18, 2026, NervGen Pharma Corp. (the “Registrant” or “Company”) announced the appointment of Dr. Sam Jackson as Chief Medical Officer, effective December 7, 2026 (the “Effective Date”). Dr. Jackson will report directly to the Chief Executive Officer. A copy of the press release announcing Dr. Jackson’s appointment is filed hereto as Exhibit 99.1.

 

Dr. Jackson, age 60, brings more than 20 years of industry experience leading clinical development for novel neurologic, immunologic and ophthalmic programs. Dr. Jackson previously served as the Chief Medical Officer of Aditum Bio, a biotechnology investment and venture capital firm, where he managed the neuroscience portfolio from August 2025 to December 2026. Prior to that, Dr. Jackson held senior clinical roles at clinical stage and public biotechnology companies. He was Chief Medical Officer of Neuron23 Inc., from April 2022 to May 2025, and Chief Medical Officer (interim) / Senior Vice President Clinical Development at Alector, Inc. (Nasdaq: ALEC), from April 2020 to April 2022. Dr. Jackson is a board-certified physician and received his MD from the University of Pennsylvania, an MBA from The Wharton School at the University of Pennsylvania and a BA from Stanford University.

 

Pursuant to an offer letter (the “Offer Letter”), signed November 16, 2026, between NervGen US Inc., a wholly owned subsidiary of the Company (“NervGen U.S.”), and Dr. Jackson governing the terms of his employment, Dr. Jackson will be paid an annualized base salary of $525,000. Beginning with fiscal year 2027, he will be eligible to receive an annual incentive bonus with a target of 40% of his base salary, based on the achievement of Company and individual performance objectives established by the Compensation Committee of the Board (the “Committee”). Pursuant to a separate sign-on bonus agreement (the “Bonus Agreement”), Dr. Jackson will also receive a one-time sign-on bonus of $208,000 in lieu of any 2026 annual bonus. The sign-on bonus is payable in two installments: $100,000 following the Effective Date and $108,000 on or after March 31, 2027, subject to Dr. Jackson's continued employment through such date, and subject to certain adjustments set forth in the Bonus Agreement.

 

The Company will grant Dr. Jackson stock options (the “Options”) to purchase up to 1,156,135 common shares of the Company, effective on the Effective Date, with an exercise price per share equal to the closing price of the Company's common shares on the Nasdaq Capital Market on the Effective Date. The Options will be exercisable for a period of ten years and are scheduled to vest over a four-year period, with 25.0% vesting on the first anniversary of the Effective Date and the remaining 75.0% vesting in thirty-six substantially equal monthly installments thereafter, subject to Dr. Jackson’s continued service through each applicable vesting date. On the Effective Date, and subject to the terms of the Offer Letter, the Company will also grant Dr. Jackson 50,000 restricted share units, which vest in full only if at least 150 participants have been randomized and enrolled in the RESTORE study on or before August 1, 2027 and Dr. Jackson remains in service through such milestone.

 

In addition, the Offer Letter provides that Dr. Jackson will be eligible to participate in the employee benefit plans made available to the Company’s senior executives. It also provides that he will enter into the Company’s standard form of indemnity agreement and be covered under its directors’ and officers’ liability insurance.

 

Pursuant to the Offer Letter, if Dr. Jackson’s employment is terminated by NervGen U.S. without cause or by Dr. Jackson for good reason outside a change in control period, NervGen U.S. is obligated to (1) continue to pay Dr. Jackson’s base salary for nine months, (2) pay any earned but unpaid annual bonus for the prior fiscal year and (3) pay the employer portion of his health coverage premiums under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), for up to nine months. If such a termination occurs within three months before or twelve months after a change in control, Dr. Jackson will be entitled to (1) a lump sum payment equal to twelve months of base salary plus 100% of his target bonus, (2) any earned but unpaid prior-year bonus, (3) COBRA premiums for up to twelve months and (4) the vesting of all outstanding and unvested time-based equity awards. Severance benefits are conditioned on Dr. Jackson’s execution of a general release of claims. All incentive-based compensation is subject to the Company's Compensation Recovery Policy.

 

The foregoing descriptions of the Offer Letter and Bonus Agreement do not purport to be complete and are subject to and qualified in their entirety by reference to the full text of the Offer Letter and Bonus Agreement. A copy of the Offer Letter and Bonus Agreement are filed as Exhibit 10.1 to this Report on Form 6-K.

 

 

 

INCORPORATION BY REFERENCE

 

This Report on Form 6-K, including Exhibits 10.1 and 99.1, is incorporated by reference into the Registrant’s Registration Statement on Form F-10 (File No. 333-296217) and the Registrant’s Registration Statements on Form S-8 (File Nos. 333-292927 and 333-295632), to be a part thereof from the date on which this Report on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit    
     
10.1   Offer Letter and Sign-On Bonus Agreement by and between NervGen U.S. and Sam Jackson, signed November 16, 2026.
99.1   Press Release, dated November 18, 2026.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  NERVGEN PHARMA CORP.
     
Date: November 18, 2026 By: /s/ Adam Rogers  
    Name: Adam Rogers
    Title: Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

 

 

NervGen Appoints Neuroscience Drug Development Leader Sam Jackson, MD, MBA, as Chief Medical Officer

 

·Dr. Jackson brings expertise in innovative neuroscience trial design, leading pivotal Phase 3 studies and supporting FDA approval

 

·He will lead execution of the ongoing Phase 3 RESTORE study and support clinical expansion of NVG-291 as a potential pipeline-in-a-product

 

MIAMI – November 18, 2026 – NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the appointment of Sam Jackson, MD, MBA, as Chief Medical Officer. Dr. Jackson will work alongside the Chief Executive Officer and Board of Directors to shape and execute the Company’s clinical development strategy.

 

Dr. Jackson has extensive experience in designing and executing clinical trials in neuroscience, most recently in cervical dystonia, Parkinson’s disease, Alzheimer’s disease and frontotemporal dementia. He has led clinical teams, designed cutting-edge clinical trials, built development organizations and contributed to regulatory submissions resulting in FDA approval.

 

“Sam is an accomplished physician-scientist and proven drug developer with expertise in innovative neuroscience trial design and experience advancing therapies through pivotal development and approval,” said Adam Rogers, MD, President and Chief Executive Officer of NervGen. “We are thrilled to welcome him to NervGen as we continue to strengthen our organization, advance through late-stage development and seek to realize the potential of NVG-291 as a pipeline-in-a-product. Sam will be instrumental in shaping our strategy for additional indications and strengthening our execution of RESTORE to deliver what could be the first therapy to enable the nervous system to repair itself.”

 

Dr. Jackson most recently served as Chief Medical Officer, Neuroscience at Aditum Bio, leading clinical development teams across its neuroscience portfolio. Previously, he was Chief Medical Officer at Neuron23, where he designed and implemented the first global Phase 2 trial in Parkinson’s disease incorporating a companion diagnostic and a digital primary endpoint. At Alector, he served as Senior Vice President of Clinical Development and interim Chief Medical Officer and was clinical lead for the pivotal Phase 3 INFRONT-3 trial in frontotemporal dementia and the Phase 2 INVOKE-2 trial in Alzheimer’s disease.

 

As Chief Medical Officer at Alkahest, Dr. Jackson built the clinical organization and initiated multiple Phase 2 trials across neurological and ophthalmic indications. As Executive Director of Clinical Development and Drug Safety at Dynavax Technologies, he was clinical lead and medical monitor for the 8,500-patient pivotal Phase 3 trial of HEPLISAV-B, a hepatitis B vaccine, and contributed to the regulatory submission that led to FDA approval. Earlier in his career, he held clinical development roles at Genentech and Amgen.

 

“NervGen’s novel approach to overcoming the inhibitory effects of chondroitin sulfate proteoglycans (CSPGs) with a subcutaneously administered therapy is very exciting, and the findings from the Phase 1b/2a CONNECT SCI study reinforce my confidence in NVG-291’s transformative potential for people living with spinal cord injury and other forms of nervous system damage,” said Sam Jackson, MD, MBA, Chief Medical Officer of NervGen. “I look forward to advancing NVG-291 through RESTORE toward potential regulatory approval and realizing its broader potential across additional indications associated with CSPG upregulation.”

 

Dr. Jackson is a board-certified emergency physician. He earned his undergraduate degree from Stanford University and his MD and MBA from the University of Pennsylvania, where he was a Twenty-First Century Scholar. He completed his emergency medicine residency at the University of California, Davis Medical Center and his medical toxicology fellowship at Banner Good Samaritan Hospital in Phoenix.

 

 

 

 

 

 

About the Phase 3 RESTORE Study

 

RESTORE is a multicenter, randomized, double-blind, placebo-controlled Phase 3 registrational study evaluating the efficacy and safety of NVG-291 in adults living with chronic traumatic cervical motor-incomplete SCI. The study is expected to enroll approximately 150 participants across the United States and Canada. The study’s primary endpoint assesses improvement in hand function, a leading recovery priority for individuals with cervical SCI, as measured by GRASSP Quantitative Prehension. Secondary endpoints and blinded participant interviews will provide additional insight into functional independence and quality of life. Eligible participants are one to ten years following a traumatic SCI, have a motor level at C7 or higher on both sides and have an American Spinal Injury Association (ASIA) Impairment Scale classification of C or D. Participants will be randomized 1:1 to receive NVG-291 or placebo by once-daily subcutaneous injection for 12 weeks, followed by a four-week observation period. An optional 12-week open-label extension is planned following study completion. For additional information, including eligibility criteria and study locations, visit ClinicalTrials.gov (identifier: NCT07799532).

 

About NervGen

 

NervGen (NASDAQ: NGEN) is a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide designed to counteract the inhibitory effects of chondroitin sulfate proteoglycans. NVG-291 has received Breakthrough Therapy designation from the FDA for the treatment of chronic traumatic cervical motor-incomplete SCI, based on preliminary clinical evidence from the Phase 1b/2a CONNECT SCI study indicating the potential for substantial improvement over available therapy on one or more clinically significant endpoints. NVG-291 has also received FDA Fast Track designation and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.

 

 

 

 

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (collectively, “forward-looking statements”). Statements regarding the Company’s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, and other future events or developments constitute forward-looking statements. The words “may”, “will”, “would”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “likely” or “potential”, or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the potential benefits of Breakthrough Therapy designation; Dr. Jackson’s anticipated contributions to the Company’s clinical development strategy, medical affairs activities and execution of RESTORE; the design, conduct, expected enrollment and anticipated timelines of the RESTORE study, including the planned open-label extension; the Company’s plans to advance NVG-291 toward potential regulatory approval and expand its clinical development into additional indications; the potential therapeutic benefits and broader applications of NVG-291, including its potential as a pipeline-in-a-product and to enable the nervous system to repair itself; the development and potential therapeutic benefits of the Company’s product candidates; and other factors described in the “Risk Factors” section of the Company’s most recently filed Annual Information Form and Annual Report on Form 40-F/A, its amended and restated management’s discussion and analysis for the year ended December 31, 2025, and subsequent filings with Canadian securities regulators and the U.S. Securities and Exchange Commission. These documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the SEC’s website at www.sec.gov. Breakthrough Therapy designation does not guarantee regulatory approval of NVG-291, and results from earlier clinical studies may not be predictive of results from subsequent studies. Readers should not place undue reliance on forward-looking statements made in this news release. Unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

 

Contacts

 

On365 Partners, Investor Relations

ir@nervgen.com

203.293.8091

 

 

 

 

Filing Exhibits & Attachments

2 documents

Keep reading